Bacterial Vaginosis and Cancer Risk
Bacterial vaginosis (BV) does not directly cause cancer, but it significantly increases the risk of acquiring and maintaining high-risk HPV infections, which are the causative agents of cervical cancer. The relationship is indirect: BV acts as a cofactor that facilitates HPV persistence and progression to precancerous cervical lesions, rather than being an independent carcinogen 1, 2.
The Mechanistic Pathway
The evidence demonstrates a clear stepwise relationship:
BV disrupts the protective vaginal environment by depleting Lactobacillus species that normally maintain acidic pH and produce antimicrobial compounds 3, 4. This creates conditions favorable for HPV acquisition and persistence.
Women with BV have a 33% increased risk of acquiring new HPV infections (RR 1.33) and a 14% increased risk of HPV persistence (RR 1.14), with even stronger associations for oncogenic HPV types (RR 1.18) 1.
The combination of BV and high-risk HPV dramatically amplifies risk: Women with both conditions face approximately double the risk of developing high-grade cervical lesions and cancer (RR 2.01) compared to those without BV 1, 5.
Recent 2026 data from Kenya confirms that BV increases HPV persistence risk by 38%, and importantly, BV resolution significantly reduces this risk (aOR 5.40), demonstrating that treating BV may help clear HPV infections 2.
Clinical Implications
The key point is that BV itself is not carcinogenic—HPV is the necessary causative agent for cervical cancer 6. However, BV creates a permissive environment through:
- Chronic inflammation that enhances HPV E6/E7 oncogenic activity 7
- Epithelial barrier disruption allowing deeper viral penetration 7
- Increased viral loads in Lactobacillus-depleted communities 7
Common pitfall: Do not interpret these findings as suggesting BV screening for cancer prevention. The established guidelines focus on HPV-based cervical cancer screening, not BV screening 6. The 2002 BV screening guidelines address only pregnancy-related outcomes, not cancer 8.
What This Means for Practice
For cervical cancer prevention, the priority remains HPV vaccination and regular cervical cancer screening per USPSTF guidelines 6. However:
- Treat symptomatic BV promptly when diagnosed, as this may reduce HPV persistence risk 2
- Women with persistent HPV infections should be evaluated for BV as a potentially modifiable cofactor
- BV is not an indication for altered cervical cancer screening intervals—follow standard HPV/cytology-based protocols 6
The most recent high-quality evidence from 2026 reinforces that while BV significantly impacts HPV dynamics, it does not independently predict histologic cervical lesions when HPV status is accounted for 9. The cancer risk pathway requires HPV as the essential driver, with BV acting as an accelerant rather than an initiator 7, 10.
Regarding other cancers: The provided evidence addresses only cervical cancer. There is no data presented linking BV to other cancer types, and such associations are not established in the medical literature.